US

Hans K Hegetschweiler

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 1988.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans K Hegetschweiler. Retrieved from https://idiyas.com/inventor/hans-k-hegetschweiler

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal1 out of 834,453 
Other
 patents

Years Active: 1988

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Hans K Hegetschweiler

Introduction

Hans K Hegetschweiler is a notable inventor based in the United States. He is recognized for his contributions to the field of pharmaceuticals, particularly through his innovative patent. His work has implications for the development of new therapeutic compounds.

Latest Patents

Hegetschweiler holds a patent for "All-cis-1,3,5-triamino-2,4,6,-cyclohexanetriol derivatives, their use." This patent includes compounds that correspond to a specific general formula, wherein various groups can represent hydrogen atoms, alkyl groups, or CO-alkyl groups. The patent also discusses the preparation processes and pharmaceutical applications of these compounds.

Career Highlights

Throughout his career, Hegetschweiler has made significant strides in the pharmaceutical industry. His innovative approach to chemical compounds has led to advancements in drug development. He has been instrumental in exploring new avenues for therapeutic applications.

Collaborations

Hegetschweiler has worked alongside notable colleagues such as Isidor Erni and Walter T Schneider. Their collaborative efforts have contributed to the success of various projects and innovations in their field.

Conclusion

Hans K Hegetschweiler's contributions to the field of pharmaceuticals through his patent and collaborative work highlight his role as an influential inventor. His innovative compounds have the potential to impact therapeutic practices significantly.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…